Scarica l'app Stockscreener
39.87
0.30%
0.12
Precedente Chiudi:
$39.75
Aprire:
$39.69
Volume 24 ore:
2.94M
Relative Volume:
1.16
Capitalizzazione di mercato:
$6.17B
Reddito:
$15.06M
Utile/perdita netta:
$-250.69M
Rapporto P/E:
-22.46
EPS:
-1.7748
Flusso di cassa netto:
$-209.28M
1 W Prestazione:
+0.45%
1M Prestazione:
+0.71%
6M Prestazione:
+59.61%
1 anno Prestazione:
+216.43%
Intervallo 1D:
$39.69
$39.90
Intervallo di 1 settimana:
$39.64
$39.90
Portata 52W:
$12.30
$40.26
Centessa Pharmaceuticals Plc Adr Stock (CNTA) Company Profile
Nome
Centessa Pharmaceuticals Plc Adr
Settore
Industria
Telefono
44 7391 789784
Indirizzo
3RD FLOOR, ALTRINCHAM, CHESHIRE
Compare CNTA vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CNTA
Centessa Pharmaceuticals Plc Adr
|
39.87 | 6.15B | 15.06M | -250.69M | -209.28M | -1.7748 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Centessa Pharmaceuticals Plc Adr Stock (CNTA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-13 | Downgrade | Truist | Buy → Hold |
| 2026-02-24 | Iniziato | Wolfe Research | Outperform |
| 2025-12-10 | Ripresa | Oppenheimer | Outperform |
| 2025-10-28 | Iniziato | Stephens | Overweight |
| 2025-09-03 | Iniziato | Wells Fargo | Overweight |
| 2025-08-29 | Ripresa | Oppenheimer | Outperform |
| 2025-07-21 | Iniziato | Truist | Buy |
| 2025-05-28 | Iniziato | Needham | Buy |
| 2025-05-08 | Iniziato | Chardan Capital Markets | Buy |
| 2025-03-31 | Iniziato | Piper Sandler | Overweight |
| 2025-01-07 | Iniziato | TD Cowen | Buy |
| 2024-09-20 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-09-19 | Iniziato | B. Riley Securities | Buy |
| 2024-07-18 | Iniziato | Oppenheimer | Outperform |
| 2023-11-15 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-10-26 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2023-06-21 | Iniziato | Evercore ISI | Outperform |
| 2023-06-12 | Iniziato | Guggenheim | Buy |
| 2023-03-17 | Iniziato | SVB Securities | Outperform |
| 2022-08-12 | Downgrade | Morgan Stanley | Overweight → Underweight |
| 2022-06-17 | Iniziato | BMO Capital Markets | Outperform |
| 2022-06-03 | Downgrade | Jefferies | Buy → Hold |
| 2022-02-11 | Iniziato | Goldman | Neutral |
Mostra tutto
Centessa Pharmaceuticals Plc Adr Borsa (CNTA) Ultime notizie
Centessa (NASDAQ: CNTA) investors approve Eli Lilly acquisition scheme - Stock Titan
TD Asset Management Inc Decreases Stake in Centessa Pharmaceuticals PLC Sponsored ADR $CNTA - MarketBeat
Gold gains over 1%; FactSet Research raises FY2026 outlook - MSN
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger—RAMP, NEE, CNTA, and HCBN - GlobeNewswire Inc.
Eli Lilly, Centessa Pharmaceuticals receive US green light - MLex
HSR waiting period lapses for Centessa (CNTA) sale to Eli Lilly under UK scheme - Stock Titan
LLY to buy neuroscience biotech Centessa Pharmaceuticals in $7.8B deal - MSN
Centessa Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Centessa Pharmaceuticals plcCNTA - ChartMill
Centessa (NASDAQ: CNTA) to be acquired by Lilly for $38 plus up to $9 CVR - Stock Titan
Is It Too Late To Consider Centessa Pharmaceuticals (CNTA) After A 191% One Year Surge? - Yahoo Finance
Centessa Pharmaceuticals (NASDAQ:CNTA) Reaches New 12-Month HighStill a Buy? - MarketBeat
LLY Stock Jumps After Q1 Earnings Beat, 2026 Guidance Raised - TradingView
Apellis Pharmaceuticals, Centessa Pharmaceuticals, Agios Pharmaceuticals and other big stocks moving higher on Tuesday - MSN
Centessa (NASDAQ: CNTA) schedules 2026 AGM and advisory pay vote - Stock Titan
38,432 Shares in Centessa Pharmaceuticals PLC Sponsored ADR $CNTA Acquired by B. Metzler seel. Sohn & Co. AG - MarketBeat
Should You Buy, Sell or Hold Lilly Stock Before Q1 Earnings? - TradingView
Wells Fargo Downgrades Centessa Pharmaceuticals ADR to Equal Weight From Overweight, Adjusts Price Target to $42 From $35 - marketscreener.com
Lilly to buy Centessa (NASDAQ: CNTA) for $38/ share plus $9 CVR - Stock Titan
Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) Given Consensus Rating of "Hold" by Analysts - MarketBeat
Are APLS, CNTA, KZR Obtaining Fair Deals for their Shareholders? - Finviz
Are APLS, KORE, CNTA Obtaining Fair Deals for their Shareholders? - Sahm
Free cash flow per share of Centessa Pharmaceuticals PLC ADR – MUN:260 - TradingView
Deal Dispatch: McCormick, Unilever Merge, Sysco Acquires Jetro Restaurant Depot For $29 Billion, QVC Considers Bankruptcy - Sahm
This Akamai Technologies Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday - Sahm
Centessa Pharmaceuticals Plc Adr Azioni (CNTA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Centessa Pharmaceuticals Plc Adr Azioni (CNTA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Anderson Karen M. | Chief People Officer |
Mar 26 '26 |
Sale |
30.12 |
41,076 |
1,237,382 |
62,085 |
| Weinhoff Gregory M | Chief Business Officer |
Mar 26 '26 |
Option Exercise |
3.85 |
23,998 |
92,392 |
89,923 |
| Weinhoff Gregory M | Chief Business Officer |
Mar 26 '26 |
Sale |
30.00 |
23,998 |
719,940 |
65,925 |
2.60%
0.94%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):